×

Piperidine and azepine derivatives as prokineticin receptor modulators

  • US 10,160,745 B2
  • Filed: 09/12/2017
  • Issued: 12/25/2018
  • Est. Priority Date: 08/08/2013
  • Status: Active Grant
First Claim
Patent Images

1. A pharmaceutical composition comprising a compound selected from the group consisting of:

  • racemic 5-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine;

    a mixture of R and S enantiomers of 5-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine;

    5-{[(3R)-3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine;

    racemic 4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine;

    a mixture of R and S enantiomers of 4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl} carbonyl)-1-methyl-1H-pyrazol-3-amine;

    4-({(3R)-3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine;

    4-({(3S)-3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine; and

    pharmaceutically acceptable salts thereof,in association with a pharmaceutically acceptable adjuvant, diluent or carrier, and optionally one or more other therapeutic agents.

View all claims
  • 0 Assignments
Timeline View
Assignment View
    ×
    ×